The Use Of Transdermal Drug Delivery In Depression And Attention Deficit Hyperactivity Disorder Are Poised To Provide Substantial Growth For The Industry.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c46153) has announced the addition of "U.S. Transdermal transdermal /trans·der·mal/ (-der´m'l) entering through the dermis, or skin, as in administration of a drug via ointment or patch. trans·der·mal adj. Through or by way of the skin. Drug Delivery Markets" to their offering. This Frost & Sullivan research service entitled en·ti·tle tr.v. en·ti·tled, en·ti·tling, en·ti·tles 1. To give a name or title to. 2. To furnish with a right or claim to something: U.S. Transdermal Drug Delivery Market provides pipeline analysis, forecasts, and technology overviews. In this research, Frost & Sullivans expert analysts thoroughly examine the following markets: allergy, osteoporosis osteoporosis (ŏs'tēō'pərō`sĭs), disorder in which the normal replenishment of old bone tissue is severely disrupted, resulting in weakened bones and increased risk of fracture; osteopenia , pain management, vaccines, and sexual dysfunction sexual dysfunction Inability to experience arousal or achieve sexual satisfaction under ordinary circumstances, as a result of psychological or physiological problems. . Market Sectors Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this analysis: * Pain Management * Hormone * Central Nervous System * Cardiovascular Technologies The following technologies are covered in this research: * Passive Patches * Active Patches Market Overview The transdermal drug delivery market is entering a new phase in which pain management is no longer the growth driver for the industry. Diseases and disorders of the central nervous system are providing excellent opportunities for transdermal drug delivery with two new products launched in early 2006. The use of transdermal drug delivery in depression and attention deficit hyperactivity disorder attention deficit hyperactivity disorder (ADHD), formerly called hyperkinesis or minimal brain dysfunction, a chronic, neurologically based syndrome characterized by any or all of three types of behavior: hyperactivity, distractibility, and impulsivity. are poised to provide substantial growth for the industry and counteract the loss of patent protection of the largest transdermal drug, Duragesic. A multitude of new products are in development covering all three categories of pain management opioid opioid /opi·oid/ (o´pe-oid) 1. any synthetic narcotic that has opiate-like activities but is not derived from opium. 2. any of a group of naturally occurring peptides, e.g. , non-steroidal anti-inflamatory drugs, and topical pain relief. These new products are expected to provide new therapy options for patients as well as growth of the market. The transdermal drug delivery market was solely based on passive patch technology that relied on simple diffusion across the skin. With the approval of Synera and IONSYS, active patches utilizing an external energy source are now on the market. Active patches offer a wider array of capabilities allowing for delivery of compounds over 500 daltons and those with challenging physical properties, allowing many companies to develop active patches to deliver pain management drugs, proteins, and vaccines to better control delivery and add value to patients disease management. Passive patch technology is still developing as well, creating smaller patches with better adhesion adhesion /ad·he·sion/ (ad-he´zhun) 1. the property of remaining in close proximity. 2. the stable joining of parts to one another, which may occur abnormally. 3. . These patches continue to control the hormone market and CNS See Continuous net settlement. CNS See continuous net settlement (CNS). segments with CNS providing the most growth due to entry into new disease indications. For more information visit http://www.researchandmarkets.com/reports/c46153 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion